Endpoint · searchGETclinicalintelpulse.theaslangroupllc.com /api/clinical/mechanism-map ?condition=Disease+%E2%80%94+e.g.+%22Treatment-Resistant+Depression%22+%7C+%22ALS%22+%7C+%22Lupus%22+%7C+%22Multiple+Sclerosis%22+%7C+%22Prostate+Cancer%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&mechanism=Optional+%E2%80%94+specific+mechanism+to+focus+on%2C+e.g.+%22BTK+inhibitor%22+%7C+%22IL-17%22+%7C+%22CAR-T%22
Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings…
Read more
Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings, with key publications. Worldwide. For drug-discovery and VC agents.Overview
Grade?
UNRATED
0 of 30 paid calls toward a letter
Price
$0.20 per call
Paid calls
none yet
delivery unknown until someone pays
More info
Seller?
URL
https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map?condition=Disease+%E2%80%94+e.g.+%22Treatment-Resistant+Depression%22+%7C+%22ALS%22+%7C+%22Lupus%22+%7C+%22Multiple+Sclerosis%22+%7C+%22Prostate+Cancer%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&mechanism=Optional+%E2%80%94+specific+mechanism+to+focus+on%2C+e.g.+%22BTK+inhibitor%22+%7C+%22IL-17%22+%7C+%22CAR-T%22
Seen
first 35 days ago · last 15 days ago
53 free handshakes
Payment
Pays through
x402
Offered on?
algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k, Polygon, eip155:143, eip155:196, Arbitrum, eip155:480, eip155:56, Base USDC, eip155:999, Solana, xrpl:0
Listed on?
Polygon, Arbitrum, Base, Solana
Score, from free handshakes onlyweights 2026.09.5
UN
RATED
RATED
0.728 liveness verified, no letter
To a letter · 30 paid calls
0 of 30
Held down by latency p95 · gap to 1.000 is 0.272: 0.109 uncertain ? + 0.163 short ? · 0.072 to B
| Component | Weight | Measured | Lower bound ? | Adds | Short ? | Uncertain ? | |
|---|---|---|---|---|---|---|---|
| latency p95costs the most it answered as fast as its class |
0.20 | 0.19 | 0.000 | 0.000 | −0.163 | −0.037 | |
| liveness it answered at all |
0.60 | 1.00 | 0.879 | 0.528 | 0 | −0.072 | |
| price stability the price stayed where it was listed |
0.20 | 1.00 | 1.000 | 0.200 | 0 | 0 | |
| Composite | 1.00 | 0.728 | gap to 1.000 = 0.272 · 0.163 short · 0.109 uncertain | 0.728 | −0.163 | −0.109 |
Not measured: correctness · nobody paid; honesty · nobody paid; schema conformance · no answer had a published shape to check
The multiplication, written out
0.200 × 0.000 latency p95
+ 0.600 × 0.879 liveness
+ 0.200 × 1.000 price stability
= 0.728 → UNRATED: 51 of 30 paid calls weights 2026.09.5 · 51 samples · seed cap_01M1A51TFT8Q96EVNH8KW7FTDZ|2026-08-27T00:51:40.247Z|2026.09.5
Verify it yourself
npx teppi-check https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map?condition=Disease+%E2%80%94+e.g.+%22Treatment-Resistant+Depression%22+%7C+%22ALS%22+%7C+%22Lupus%22+%7C+%22Multiple+Sclerosis%22+%7C+%22Prostate+Cancer%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&mechanism=Optional+%E2%80%94+specific+mechanism+to+focus+on%2C+e.g.+%22BTK+inhibitor%22+%7C+%22IL-17%22+%7C+%22CAR-T%22curl -s https://api.teppi.xyz/v1/trust/cap_01M1A51TFT8Q96EVNH8KW7FTDZ